Breaking News

U.S. May Home Prices Rise 0.4% From Previous Month: FHFA
Tweet TWEET

The Scripps Research Institute Announces New Research and License Agreement with Janssen Pharmaceuticals, Inc.

 The Scripps Research Institute Announces New Research and License Agreement
                      with Janssen Pharmaceuticals, Inc.

PR Newswire

LA JOLLA, Calif., May 7, 2013

LA JOLLA, Calif., May 7, 2013 /PRNewswire-USNewswire/ --The Scripps Research
Institute (TSRI) today announced a five-year agreement with Janssen
Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in
the infectious disease area, with the initial project targeting the influenza
virus. Under the agreement Janssen will receive certain license rights to the
results of the research. Janssen Pharmaceuticals will collaborate in the
research on influenza through its Crucell Vaccine Institute.

"We're delighted to partner with Janssen in this work that could have a
significant impact on human health," said Michael A. Marletta, president and
CEO of TSRI. "The new agreement leverages the institute's significant
strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest, TSRI's vice president for business development, added, "This
deal is the latest example of our corporate partnership strategy, in which we
seek focused collaborations to match companies' specific areas of interest
with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly
by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have
resulted in several high-impact publications, most recently in August 2012 in
the journal Science.

Seasonal flu typically causes more than 200,000 hospitalizations and 36,000
deaths every year in the United States, according to estimates by the U.S.
Centers for Disease Control. Pandemics pose a greater danger—the Spanish Flu
of 1918-1919 may have killed 50 million people worldwide.

The new strategic collaboration with Janssen follows TSRI's announcement of a
five-year agreement with Bristol-Myers Squibb last June; that agreement
covered the development of chemistry methodologies and related work.

Forrest notes that promising future areas for corporate partnerships at TSRI
include Oncology, Neurodegeneration and Immunology.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent,
not-for-profit organizations focusing on research in the biomedical sciences.
Over the past decades, TSRI has developed a lengthy track record of major
contributions to science and health, including laying the foundation for new
treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases.
The institute employs about 3,000 people on its campuses in La Jolla, CA, and
Jupiter, FL, where its renowned scientists—including three Nobel
laureates—work toward their next discoveries. The institute's graduate
program, which awards Ph.D. degrees in biology and chemistry, ranks among the
top ten of its kind in the nation. For more information, see www.scripps.edu.

SOURCE The Scripps Research Institute

Website: http://www.scripps.edu